Moonlight Therapeutics is at the forefront of developing innovative intradermal therapies aimed at transforming the treatment landscape for individuals with food allergies, particularly peanut allergies. Their lead product, MOON101, is designed to be a differentiated treatment option that utilizes a unique intradermal delivery system. This system involves an intradermal stamp that can be worn for a short duration, which has shown promising results in preclinical studies by successfully desensitizing peanut-allergic mice. The company is actively pursuing clinical trials to further investigate the efficacy and safety of MOON101 in both adults and children with peanut allergies.

In addition to its promising therapeutic approach, Moonlight Therapeutics has recently secured a multimillion-dollar grant to support clinical trials for MOON101, highlighting the potential impact of their technology in the field of allergy treatment. The company has also completed a Pre-Investigational New Drug (Pre-IND) meeting with the FDA, indicating progress in navigating the regulatory landscape for their innovative therapy. Through these efforts, Moonlight Therapeutics aims to break through existing barriers in food allergy treatment and improve the quality of life for those affected by these conditions.

United States

Moonlight Therapeutics is focused on developing safe, effective, and patient-friendly treatments for people suffering from food allergies. Our first treatment is for children and adults with peanut allergies.

Moonlight Therapeutics

Company Details